3 years ago

Personalized neoantigen vaccines: a new approach to cancer immunotherapy

Personalized neoantigen vaccines: a new approach to cancer immunotherapy
Neoantigens arise from somatic mutations that differ from wild-type antigens and are specific to each individual patient, which maximizes the number of tumor specific targets and immune responses. Decades of work has increasingly shown the potential of targeting neoantigens to generate effective clinical responses. Current clinical trials using neoantigen targeting cancer vaccines, including in combination with checkpoint blockade monoclonal antibodies, have observed potent T-cell response against those neoantigens accompanied by tumor regression in patients. Therefore, personalized peptide-based neoantigen vaccines have become a promising approach toward cancer immunotherapy.

Publisher URL: www.sciencedirect.com/science

DOI: S0968089617312208

You might also like
Discover & Discuss Important Research

Keeping up-to-date with research can feel impossible, with papers being published faster than you'll ever be able to read them. That's where Researcher comes in: we're simplifying discovery and making important discussions happen. With over 19,000 sources, including peer-reviewed journals, preprints, blogs, universities, podcasts and Live events across 10 research areas, you'll never miss what's important to you. It's like social media, but better. Oh, and we should mention - it's free.

  • Download from Google Play
  • Download from App Store
  • Download from AppInChina

Researcher displays publicly available abstracts and doesn’t host any full article content. If the content is open access, we will direct clicks from the abstracts to the publisher website and display the PDF copy on our platform. Clicks to view the full text will be directed to the publisher website, where only users with subscriptions or access through their institution are able to view the full article.